Advertisement
U.S. markets open in 3 hours 19 minutes
  • S&P Futures

    5,304.00
    -4.25 (-0.08%)
     
  • Dow Futures

    40,134.00
    -10.00 (-0.02%)
     
  • Nasdaq Futures

    18,481.75
    -22.00 (-0.12%)
     
  • Russell 2000 Futures

    2,135.60
    -2.80 (-0.13%)
     
  • Crude Oil

    81.93
    +0.58 (+0.71%)
     
  • Gold

    2,218.00
    +5.30 (+0.24%)
     
  • Silver

    24.57
    -0.19 (-0.76%)
     
  • EUR/USD

    1.0783
    -0.0047 (-0.43%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    13.00
    +0.22 (+1.72%)
     
  • GBP/USD

    1.2603
    -0.0035 (-0.28%)
     
  • USD/JPY

    151.4540
    +0.2080 (+0.14%)
     
  • Bitcoin USD

    70,631.62
    +690.94 (+0.99%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,971.00
    +39.02 (+0.49%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

What Did Proteome Sciences plc's (LON:PRM) CEO Take Home Last Year?

In 2016 Jeremy Rupert Haigh was appointed CEO of Proteome Sciences plc (LON:PRM). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. After that, we will consider the growth in the business. And finally - as a second measure of performance - we will look at the returns shareholders have received over the last few years. The aim of all this is to consider the appropriateness of CEO pay levels.

See our latest analysis for Proteome Sciences

How Does Jeremy Rupert Haigh's Compensation Compare With Similar Sized Companies?

At the time of writing, our data says that Proteome Sciences plc has a market cap of UK£9.6m, and reported total annual CEO compensation of UK£250k for the year to December 2018. Notably, the salary of UK£247k is the vast majority of the CEO compensation. We looked at a group of companies with market capitalizations under UK£153m, and the median CEO total compensation was UK£248k.

So Jeremy Rupert Haigh is paid around the average of the companies we looked at. While this data point isn't particularly informative alone, it gains more meaning when considered with business performance.

You can see a visual representation of the CEO compensation at Proteome Sciences, below.

AIM:PRM CEO Compensation, December 5th 2019
AIM:PRM CEO Compensation, December 5th 2019

Is Proteome Sciences plc Growing?

Over the last three years Proteome Sciences plc has grown its earnings per share (EPS) by an average of 39% per year (using a line of best fit). In the last year, its revenue is up 3.5%.

This shows that the company has improved itself over the last few years. Good news for shareholders. It's also good to see modest revenue growth, suggesting the underlying business is healthy. Although we don't have analyst forecasts you might want to assess this data-rich visualization of earnings, revenue and cash flow.

Has Proteome Sciences plc Been A Good Investment?

With a three year total loss of 42%, Proteome Sciences plc would certainly have some dissatisfied shareholders. This suggests it would be unwise for the company to pay the CEO too generously.

In Summary...

Remuneration for Jeremy Rupert Haigh is close enough to the median pay for a CEO of a similar sized company .

We like that the company is growing EPS, but we find the returns over the last three years to be lacking. We'd be surprised if shareholders want to see a pay rise for the CEO, but we'd stop short of calling their pay too generous. So you may want to check if insiders are buying Proteome Sciences shares with their own money (free access).

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Advertisement